BioSpace News Archive

ADC Therapeutics to Participate in Cowen 41 st Annual Health Care Conference

Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced the appointment of Cynthia Pussinen as chief technical officer (CTO).

– B-SIMPLE4 pivotal Phase 3 trial evaluating SB206 as a treatment for molluscum contagiosum progressing with top-line efficacy results targeted before the end of Q2 2021 – – Company targeting initiating preclinical studies for intranasal formulation of berdazimer sodium for COVID-19 program, SB019, in Q1 2021 – – Ongoing evaluations for strategic partnering opportunities to leverage broader pipeline to secure next phase of growth –

Research, innovative headways, and expanding R&D exercises in science and therapeutic field is powering the global market for B-Glucuronidase Enzymes

Fact.MR, Rockville: Award-winning market research firm Fact.MR has published the uraemia treatment market study.

The rapidly growing global geriatric population is playing an instrumental role in the growth of the global artificial tears market.

Non-insulin treatments are generally utilized in type 2 diabetes patients, where body either doesn’t deliver enough insulin or can’t successfully utilize the insulin it produces.

Elekta announced that Johan Adebäck has been appointed as permanent Chief Financial Officer with immediate effect.

The global market for over-the-counter diagnostics is expected to witness a noteworthy growth in the next few years.

Dental and dental hygiene students and staff remain among the few groups on-site nearly daily at universities and colleges across Canada.